Changes in airway inflammation with pseudomonas eradication in early cystic fibrosis

被引:11
|
作者
Garratt, Luke W. [1 ]
Breuer, Oded [1 ,2 ,3 ]
Schofield, Craig J. [1 ]
McLean, Samantha A. [1 ]
Laucirica, Daniel R. [1 ,4 ]
Tirouvanziam, Rabindra [5 ,6 ]
Clements, Barry S. [1 ,3 ]
Kicic, Anthony [1 ,3 ,4 ,7 ,8 ]
Ranganathan, Sarath [9 ,10 ,11 ]
Stick, Stephen M. [1 ,3 ,4 ]
机构
[1] Univ Western Australia, Wal Yan Resp Res Ctr, Telethon Kids Inst, Nedlands, WA, Australia
[2] Hadassah Hebrew Univ, Dept Pediat, Pediat Pulm Unit, Med Ctr, Jerusalem, Israel
[3] Perth Childrens Hosp, Dept Resp & Sleep Med, Nedlands, WA, Australia
[4] Univ Western Australia, Fac Hlth & Med Sci, Nedlands, WA, Australia
[5] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA
[6] Childrens Healthcare Atlanta, Ctr CF & Airways Dis Res, Atlanta, GA USA
[7] Univ Western Australia, Ctr Cell Therapy & Regenerat Med, Sch Med & Pharmacol, Subiaco, WA, Australia
[8] CurtinUniv, Sch Publ Hlth, Occupat & Environm, Bentley, WA, Australia
[9] Royal Childrens Hosp, Dept Resp Med, Parkville, Vic, Australia
[10] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[11] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
P; aeruginosa; Inflammation; Neutrophil elastase; CT; Bronchiectasis; YOUNG-CHILDREN; NEUTROPHIL ELASTASE; AERUGINOSA INFECTION; PULMONARY-FUNCTION; SPUTUM BIOMARKERS; RISK-FACTORS; THERAPY; DISEASE; BRONCHIECTASIS; EXACERBATIONS;
D O I
10.1016/j.jcf.2020.12.015
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Neutrophil elastase is a significant risk factor for structural lung disease in cystic fibrosis, and Pseudomonas aeruginosa airway infection is linked with neutrophilic inflammation and substantial respiratory morbidity. We aimed to evaluate how neutrophil elastase (NE) activity changes after P. aeruginosa eradication and influences early disease outcomes. Methods: We assessed participants in the AREST CF cohort between 20 0 0 and 2018 who had P. aeruginosa cultured from their routine annual bronchoalveolar lavage (BAL) fluid and who underwent eradication treatment and a post eradication BAL. Factors associated with persistent P. aeruginosa infection, persistent neutrophilic inflammation following eradication and worse structural lung disease one year post-eradication were evaluated. Results: Eighty-eight episodes (3 months to 6 years old) of P. aeruginosa infection were studied. Eradication was successful in 84.1% of episodes. Median activity of NE was significantly reduced post-eradication from 9.15 to 3.4 nM ( p = 0.008) but persisted in 33 subjects. High post-eradication NE levels were associated with an increased risk for P. aeruginosa infection in the next annual visit (odds ratio = 1.7, 95% confidence interval 1.1-2.7, p = 0.014). Post-eradication NE levels (difference, 0.8; 95% confidence interval, 0.1-1.5) and baseline bronchiectasis computed tomography (CT) score (difference, 0.4; 95% confidence interval, 0.1-0.8) were the best predictors of bronchiectasis progression within 1 year (backward stepwise linear regression model, R 2 = 0.608, P < 0.001), independent of eradication. Conclusion: In children with CF, NE activity may persist following successful P. aeruginosa eradication and is significantly associated with bronchiectasis progression. Evaluating strategies to diminish neutrophilic inflammation is essential for improving long-term outcomes. (c) 2020 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:941 / 948
页数:8
相关论文
共 50 条
  • [31] NET formation induced by Pseudomonas aeruginosa cystic fibrosis isolates measured as release of myeloperoxidase-DNA and neutrophil elastase-DNA complexes
    Yoo, Dae-Goon
    Floyd, Madison
    Winn, Matthew
    Moskowitz, Samuel M.
    Rada, Balazs
    IMMUNOLOGY LETTERS, 2014, 160 (02) : 186 - 194
  • [32] Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis
    White, Laura
    Mirrani, Ghazi
    Grover, Mark
    Rollason, Judith
    Malin, Adam
    Suntharalingam, Jay
    RESPIRATORY MEDICINE, 2012, 106 (03) : 356 - 360
  • [33] Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis
    Orriols, Ramon
    Hernando, Rosana
    Ferrer, Adelaida
    Terradas, Sonia
    Montoro, Bruno
    RESPIRATION, 2015, 90 (04) : 299 - 305
  • [34] Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
    Akkerman-Nijland, Anne M.
    Yousofi, Mina
    Rottier, Bart L.
    Van der Vaart, Hester
    Burgerhof, Johannes G. M.
    Frijlink, Henderik W.
    Touw, Daan J.
    Koppelman, Gerard H.
    Akkerman, Onno W.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14
  • [35] Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic
    Davidson, A. George F.
    Chilvers, Mark A.
    Lillquist, Yolanda P.
    CURRENT OPINION IN PULMONARY MEDICINE, 2012, 18 (06) : 615 - 621
  • [36] Sputum Biomarkers of Inflammation and Lung Function Decline in Children with Cystic Fibrosis
    Sagel, Scott D.
    Wagner, Brandie D.
    Anthony, Margaret M.
    Emmett, Peggy
    Zemanick, Edith T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (09) : 857 - 865
  • [37] Effect of domase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis
    Konstan, Michael W.
    Ratjen, Felix
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (02) : 78 - 83
  • [38] A case of failed eradication of cystic fibrosis-related sinus colonisation by Pseudomonas aeruginosa
    Linnane, Barry
    Kearse, Linda
    O'Connell, Nuala H.
    Fenton, John
    Kiernan, Miranda G.
    Dunne, Colum P.
    BMC PULMONARY MEDICINE, 2015, 15 : 1
  • [39] Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection
    Pittman, Jessica E.
    Noah, Hannah
    Calloway, Hollin E.
    Davis, Stephanie D.
    Leigh, Margaret W.
    Drumm, Mitchell
    Sagei, Scott D.
    Accurso, Frank J.
    Knowles, Michael R.
    Sontag, Marci K.
    PLOS ONE, 2017, 12 (05):
  • [40] Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy
    Cantin, Andre M.
    Hartl, Dominik
    Konstan, Michael W.
    Chmiel, James F.
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (04) : 419 - 430